Early Results of Paclitaxel Carboplatin Chemotherapy for NSCLC
Explore the clinical and paraclinical features, as well as the early outcomes of Paclitaxel Carboplatin chemotherapy in treating stage IIIB-IV non-small cell lung cancer at Thanh Nhan Hospital. Learn about the study conducted on 39 patients, the eligibility criteria, treatment methodology, and patient characteristics. Discover the impact of chemotherapy on patient outcomes and the importance of early diagnosis in lung cancer treatment.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
CLINICAL AND PARACLINICAL FEATURES; EARLY RESULTS OF PACLITAXEL CARBOPLATIN CHEMOTHERAPY IN TREATMENT THE STAGE IIIB IV NON SMALL CELL LUNG CANCER AT THANH NHAN HOSPITAL Nguy n Th nh Vinh H i Ph ng, 2017
INTRODUCTION Lung cancer was the most common cancer worldwide Vietnam has a high incidence of lung cancer in both sexes, ranking first in men and 5th in women. Early diagnosis of lung cancer is difficult, most patients are diagnosed at late stage Chemotherapy are still the choice to take palliative care and extend extra life in late-stage
AIM 1. To describe a variety of clinical features, paraclinical 2. Early results of Paclitaxel Carboplatin chemotherapy in treatment the stage IIIB VI NSCLC
METHOD 39 patients with stage IIIB IV NSCLC were treated b Paclitaxel Carboplatin regment at the Department of Oncology - Thanh Nhan Hospital from march 2015 to march 2016
METHOD Eligibility Criteria Histology: NSCLC Stage IIIB - IV PS: 0-1 First diagnosed, no perior chemotherapy No contraindications to chemotherapy Full medical record Undergone 3 cycles chemotherapy at least
METHOD Ineligible criteria Histology: SLCC Brain metastases Treatment before Prior chemotherapy
METHOD Dose Paclitaxel Carboplatin regment Paclitaxel 175 mg/m2 IV d1 Carboplatin AUC = 6 IV d1 Every 3 weeks, at least 3 cycles
METHOD 4.Ph n t ch v x l s li u - X l s li u b ng ph n m m SPSS 16.0 5. o c trong nghi n c u Ph c nghi n c u l ph c chu n C s cho ph p c a b nh vi n Thanh Nh n C s ng h p t c c a b nh nh n. Danh s ch b nh nh n kh ng n u t n. K t qu nghi n c u ch p d ng ph c v kh m v i u tr cho b nh nh n, kh ng c m c ch n o kh c
RESULTS 1. Patients Characteristics Table 1: Patients characteristics n 39 % 100 In total , 39 patients Age Mean Range Sex Female Male PS 0 1 Histology Adenocarcinoma Squamous cell Large cell 57 33 77 5 12,8 87,2 34 18 21 46,2 53,8 24 14 1 61,5 35,9 2,6 Stage IIIB IV 26 13 66,7 33,3 CEA < 5 ng/ml >5 ng/ml 11 28 28,2 71.8
RESULTS 1. Patients Characteristics Table 2: Clinical symptoms Symptoms n % Cough 17 43,5 Blood in sputum 8 20,5 Lymph nodes at neck 8 20,5 Chest pain 31 79,5 Trouble breathing 13 33,3 Weight loss 21 53,4 fever 3 7.7
RESULTS 2. Results Table 3: Respone rate n % Comeplete respone 0 0 Partial respone 12 30,8 Stable disease 20 51,3 Progressive disease 7 17,9 Total 39 100
RESULTS 2. Resullts Table 4: Stage Respone Respone No respone Total Stage n % n % IIIB 10 62,5 6 37,5 16 (100%) IV 2 15,4 11 84,6 13 (100%) Total 12 30,8 27 69,2 39 (100%)
RESULTS 2. Results Table 5: Histologic respone Respone Respone No respone Total Histology n % n % Adenocarcinoma 7 53,8 6 46,2 13 (100%) Squamous cell 66 24 19 76 25 (100%) Large cell Total 11 14 100 35,9 25 0 0 64,1 39 1 (100%) (100%)
RESULTS 3. Side effects Table 6: Hematologic Toxicities Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 n 34 % 87,1 n 0 % 0 n 1 % 2,6 n 4 % 10,3 n 0 % 0 Neutropenia Anemia 32 82,1 2 5,1 0 0 5 12,8 0 0 Thrombocytopenia 39 100 0 0 0 0 0 0 0 0
RESULTS 3. Side effects Table 7: Nonhematologic toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 n 0 % 0 n 0 % 0 n 0 % 0 n 0 % 0 n 0 % 0 Ure Creatinin 37 100 1 2,6 1 2,6 0 0 0 0 SGPT 34 87,2 3 7,7 2 5,1 0 0 0 0 SGOT 35 100 2 5,1 2 5,1 0 0 0 0
DISCUSION 1.Patient characteristics In total 39 patients 34 male v 5 female , the average age 57 (range 33 to 77). Belani s research, 2005, age at 64, Rosell s reseach 2002 age at 58 24 patients had Adenocarcinoma (61.5%), L Quang Huy:46.7 %, L Thu H 42.2 % Chest pain is common symptom, 31 patients 79.5 % ,Nguy n Th Minh Ph ng (2010) 82.5%, V V n V (2002) 82.5 %.
DISCUSION 2. Respone rate No patients had a complete response, partial response rate reached Patients with advanced disease will stop treatment and change other regimens..
DISCUSION 3.Side effects Common Hematologic toxicities 4 patients had grade 3 neutronemia (10.3%) 5 patients had grad 3 anemia(12,8%) No patiets had thrompocytopenia Nonhematologic toxicities: toxicit e on the liver, kidney is mild Most side effects are acceptable and no patients stop treatment because of side effects
CONCLUSION Paclitaxel carboplatin chemotherapy is an effective and safe for patients with stage IIB IV NSCLC
